Search

Trolamine

It is commonly used as a pH adjuster and surfactant in industrial and cosmetic products such as skin and hair conditioning products. … Trolamine contains small amounts of diethanolamine and ethanolamine and may also act as an antioxidant against the auto-oxidation of animal and vegetable fats [A27174].

Plecanatide

It should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age … Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC).

Fosdenopterin

In 2009 a recombinant, E. coli-produced cPMP was granted orphan drug designation by the FDA, becoming the first therapeutic option for patients with MoCD type A. … Molybdenum cofactor deficiency (MoCD) is an exceptionally rare autosomal recessive disorder resulting in a deficiency of three molybdenum-dependent enzymes: sulfite oxidase (SOX), xanthine dehydrogenase

Fluciclovine (18F)

It presents excellent diagnostic properties to be used in positron emission tomography (PET) imaging. … [A31385] Fluciclovine was developed by Blue Earth Diagnostics, Ltd. and FDA approved in May 27, 2016.[L1049]

Rezafungin

[L45633,L45658] It was subsequently approved in the EU in November of the same year. [L52745] … Rezafungin is an echinocandin antifungal drug.

Efanesoctocog alfa

episodes in patients with hemophilia A. … [A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414]

Silver citrate

Eplontersen

Eplontersen is a transthyretin-directed antisense oligonucleotide with 3 covalently linked e N-acetyl galactosamine residues for hepatic delivery. … This approval was based on positive results demonstrated in the 35-week interim analysis from the Phase 3 NEURO-TTRansform study, where a consistent improvement in the Neuropathy Impairment Score +7 (mNIS

Suzetrigine

[A264953] On January 30, 2025, suzetrigine was approved by the FDA as a first-in-class non-opioid analgesic.[L52098] … Suzetrigine is a Na_V1.8 voltage-gated sodium channel blocker with analgesic properties[A264948] Na_V1.8 is abundantly expressed in peripheral sensory nerves to play a role in pain

Elexacaftor

[A187361] The triple combination product Trikafta^TM, manufactured by Vertex Pharmaceuticals, is the first product approved for the treatment of CF in individuals who are either homo- _or_ heterozygous … [A187361] It received FDA approval in October 2019 in combination with [tezacaftor] and [ivacaftor] as the combination product Trikafta^TM.